Bailey-Wood R, Dallimore C M, Littlewood T J, Bentley D P
Br J Cancer. 1985 Oct;52(4):613-7. doi: 10.1038/bjc.1985.234.
Etoposide is being used increasingly in the treatment of a variety of malignant conditions and in conjunction with autologous bone marrow transplantation. We have examined the effect of the drug on human CFU-GM as an indication of the response of these bone marrow progenitor cells to measured plasma concentrations. When etoposide is present in the routine assay for 7 days, 50% growth of colony-forming CFU-GM occurs at a concentration of 0.0098 micrograms ml-1. When bovine serum albumin or human serum albumin is present this value is increased to 0.042 and 0.375 micrograms ml-1. Protein binding therefore plays an important part in modifying in vitro response and possibly in vivo response of these progenitor cells to etoposide.
依托泊苷越来越多地用于治疗各种恶性疾病,并与自体骨髓移植联合使用。我们已检测了该药物对人CFU-GM的影响,以此作为这些骨髓祖细胞对所测血浆浓度反应的指标。当依托泊苷在常规测定中存在7天时,集落形成CFU-GM在浓度为0.0098微克/毫升时出现50%的生长。当存在牛血清白蛋白或人血清白蛋白时,该值分别增加到0.042和0.375微克/毫升。因此,蛋白质结合在改变这些祖细胞对依托泊苷的体外反应以及可能的体内反应中起着重要作用。